Re­veal­ing heavy loss­es in new SEC fil­ing, video game ther­a­peu­tic mak­er Ak­ili de­tails an un­cer­tain fi­nan­cial fu­ture

Ak­ili In­ter­ac­tive, mak­ers of the first FDA-ap­proved video game, rode its suc­cess­es to a SPAC deal last month valu­ing the com­pa­ny at more than $1 bil­lion. But in fil­ing some of its first fi­nan­cial dis­clo­sures Mon­day, Ak­ili re­vealed it has a tough road ahead to com­mer­cial prof­its.

In an S-4 filed with the SEC, the com­pa­ny said it made on­ly about $377,000 in the first nine months of 2021 and in­curred more than $41.6 mil­lion in ex­pens­es over the same time pe­ri­od. The steep op­er­at­ing loss­es came af­ter Ak­ili was more than $25 mil­lion in the red for all of 2020 and lost $21.5 mil­lion in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER